Physician profile
Pablo E Molina
NPI 1740215805
$14,545.15
in general payments reported to CMS, 2019-2025
45 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $1,718 · 2021: $2,005 · 2022: $2,634 · 2023: $2,308 · 2024: $2,238 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,810 · Education: $57.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,810.47 |
| Education | $57.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,575.98 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,219.63 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,171.74 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $726.57 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.04 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Mallinckrodt Hospital Products INC. | $605.30 | 2020-2025 | Acthar |
| Genzyme Corporation | $593.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $544.36 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $524.22 | 2020-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $480.53 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $364.73 | 2022-2025 | Tezspire |
| Pfizer INC. | $339.89 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $333.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $331.70 | 2019-2024 | |
| Insmed, INC. | $320.35 | 2019-2025 | Arikayce, Brinsupri |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $284.36 | 2019-2025 | Xywav |
| Mylan Specialty L.P. | $271.28 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $258.75 | 2020-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $216.84 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Harmony Biosciences LLC | $162.46 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $158.96 | 2022-2025 | Sunosi |
| Baxter Healthcare | $151.88 | 2022-2025 | Ips - Nutrition, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| E.R. Squibb & Sons, L.L.C. | $139.44 | 2019-2024 | Eliquis |
| Genentech USA, INC. | $133.99 | 2019-2025 | Xolair |
| Gilead Sciences, INC. | $124.90 | 2021-2022 | |
| Philips North America LLC | $99.61 | 2019-2025 | Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Electromed, INC. | $84.95 | 2019-2024 | Smartvest |
| Verona Pharma, INC. | $74.61 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $70.12 | 2019-2020 | |
| Pulmonx Corporation | $49.29 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.12 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $42.47 | 2019 | |
| Eisai INC. | $40.22 | 2021 | |
| Advanced Respiratory, INC | $39.41 | 2019 | |
| Viatris Specialty LLC | $33.77 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $32.13 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $25.67 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $25.08 | 2024 | Lumryz |
| Pharming Healthcare, INC. | $23.11 | 2023 | Ruconest |
| Vifor Pharma, INC. | $18.55 | 2024 | Veltassa |
| Inspire Medical Systems, INC. | $16.80 | 2025 | Inspire |
| Circassia INC. | $15.91 | 2020 | |
| Shire North American Group INC | $13.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.